Navigation Links
RPCI-Led Study: FAK Inhibitor Proves Effective Against Brain Tumors in Preclinical Studies
Date:12/29/2012

Buffalo, NY (PRWEB) December 28, 2012

Researchers from Roswell Park Cancer Institute (RPCI) have published findings from a preclinical study assessing the effectiveness of a small-molecule inhibitor, CFAK-Y15, in treating some brain cancers. The paper, published in Molecular Cancer Therapeutics, demonstrates for the first time that inhibiting the protein focal adhesion kinase (FAK) with CFAK-Y15 is an effective approach to controlling growth of glioblastoma tumors, especially in combination with the standard chemotherapy agent temozolomide (Temodar).

FAK is overexpressed, or produced in excessive amounts, in tumor cells, and has been shown to play a key role in survival of cancer cells. In this study, a team led by Vita M. Golubovskaya, PhD, an Associate Professor of Oncology in the Department of Surgical Oncology, found that animal models treated with CFAK-Y15 demonstrated significantly prolonged survival compared to the control group. CFAK-Y15 provides FAK kinase-specific inhibition by upstream targeting of autophosphorylation sites on the FAK protein. It belongs to a class of ‘two for one’ compounds that also inhibit the oncoprotein Src by inhibiting its autophosphorylation.

“We found that CFAK-Y15 significantly decreased the viability of the glioblastoma cells, and in many cases appeared to cause tumor shrinkage — especially when CFAK-Y15 was given in combination with temozolomide,” noted Dr. Golubovskaya, the paper’s first author. “These compounds target FAK signaling, which is critical for cancer cell and cancer stem cell survival, especially in invasive and metastatic cancers.”

“We’re eager to see this research move to the clinical phase because of the great need for
'/>"/>

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Nature Materials study: Boosting heat transfer with nanoglue
2. New Study: Health Professionals Support Biotechnologys Use In Food Products And Sustainable Farming
3. Nature Materials study: Graphene invisible to water
4. Breaking Study: ICU Medicals Tego® Needlefree Connector Proves More Cost Effective Than Traditional Central Venous Catheter Locks
5. Karyopharm Therapeutics Announces Oral Presentation at the American College of Rheumatology (ACR) on the use of Selective Inhibitors of Nuclear Export (SINE) CRM1 Antagonists in preclinical models of Systemic Lupus Erythematosus (SLE)
6. Array BioPharma To Present Clinical Data At The 2012 ASH Meeting On ARRY-520, A KSP Inhibitor, And ARRY-614, A Dual p38/Tie2 Inhibitor
7. Kinase Inhibitors: Global Markets -- Focus on the U.S.
8. Karyopharm Therapeutics announces the Publication of Two Preclinical Studies on the Activity of Selective Inhibitors of Nuclear Export (SINE) in Acute Myeloblastic Leukemia (AML)
9. Arthritis Therapeutics Market to 2018 - Novel Oral JAK Inhibitors and Biologic Disease Modifying Anti-Rheumatic Drugs (DMARD) Will Drive Continued Growth Across Key Indications
10. Lixte Biotechnology Receives US Patent for Its Proprietary Histone Deacetylase Inhibitor
11. Karyopharm Therapeutics Announces Multiple Presentations on Selective Inhibitors of Nuclear Export (SINE) in Solid and Hematologic Malignancy Models and Spontaneous Canine Cancers at the American Association of Cancer Research (AACR) Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... Pittsburgh, PA (PRWEB) July 25, 2014 ... annual Call for Topics for Conferee Networking. These two-hour ... similar interests to meet and resolve problems, discuss new ... , The deadline to submit a topic for consideration ... at pittcon.org . The Conferee Networking committee will ...
(Date:7/25/2014)... BENSALEM, Pa. , July 25, 2014 /PRNewswire-iReach/ ... services and consulting for global corporations operating in ... will host its first annual Global User Group ... in historic Philadelphia, Pennsylvania ... Photo - http://photos.prnewswire.com/prnh/20140724/130263 ...
(Date:7/24/2014)... NY - July 24, 2014 -- Keryx Biopharmaceuticals, Inc. ... the long-term, randomized, active control Phase 3 study of ... phosphate binder, for the treatment of hyperphosphatemia in patients ... study (PhosphatE binding and iRon delivery with FErric CiTrate ... Journal of the American Society of Nephrology ( ...
(Date:7/24/2014)... Calif. , July 24, 2014  Now available ... to home. Rehealth Regenerative Therapies , located in ... and other physically active people a new health option: ... Regardless of age, countless patients suffer from joint ... activities, such as muscle tears, torn rotator cuff, tennis ...
Breaking Biology Technology:Pittcon 2015 Announces Call for Topics for Conferee Networking Sessions 2Xybion Announces It Will Host International User Conference in Philadelphia 2Xybion Announces It Will Host International User Conference in Philadelphia 3Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 4Stem Cells In Sports Injuries, Joints And Muscular Pain 2Stem Cells In Sports Injuries, Joints And Muscular Pain 3
... , , Mark Churchill and Mark Harrison, Thermo Finnigan, , ... , , Bioanalytical Method Validation , ... using , a Thermo Finnigan TSQ Quantum mass spectrometer, , ... , , , , Guidelines on Bioanalytical ...
... , , , , , , ... Beecham Pharmaceuticals , , Metabolite ... Finnigan LCQ , Series of ion trap mass spectrometers. , ... , An integral part of the process by ...
... , , , , Jack Cunniff, Philip Tiller, Michael Harvey, ... , , , , , ... using the Thermo Finnigan LCQ , Series of ion trap mass spectrometers. , ... , For more than five thousand years tea has been used in ...
Cached Biology Technology:Bioanalytical Method Intraday Validation for the Quantitation of Paroxetine , in Bovine Plasma using the TSQ Quantum Mass Spectrometer 2Bioanalytical Method Intraday Validation for the Quantitation of Paroxetine , in Bovine Plasma using the TSQ Quantum Mass Spectrometer 3Bioanalytical Method Intraday Validation for the Quantitation of Paroxetine , in Bovine Plasma using the TSQ Quantum Mass Spectrometer 4Bioanalytical Method Intraday Validation for the Quantitation of Paroxetine , in Bovine Plasma using the TSQ Quantum Mass Spectrometer 5Bioanalytical Method Intraday Validation for the Quantitation of Paroxetine , in Bovine Plasma using the TSQ Quantum Mass Spectrometer 6In-Vitro Metabolism Studies Using Data-Dependent LC/MSn 2In-Vitro Metabolism Studies Using Data-Dependent LC/MSn 3In-Vitro Metabolism Studies Using Data-Dependent LC/MSn 4In-Vitro Metabolism Studies Using Data-Dependent LC/MSn 5In-Vitro Metabolism Studies Using Data-Dependent LC/MSn 6Structural Determination of Flavonoids Using MSn 2Structural Determination of Flavonoids Using MSn 3Structural Determination of Flavonoids Using MSn 4
(Date:7/24/2014)... July 24, 2014 -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) (the ... randomized, active control Phase 3 study of Zerenex (ferric ... for the treatment of hyperphosphatemia in patients with end-stage ... binding and iRon delivery with FErric CiTrate in EsrD) ... the American Society of Nephrology ( JASN ). ...
(Date:7/24/2014)... Scientists at The New York Stem Cell Foundation ... creating a viable cell replacement therapy for multiple ... For the first time, NYSCF scientists generated induced ... of patients with primary progressive multiple sclerosis and ... these stem cells into becoming oligodendrocytes, the myelin-forming ...
(Date:7/24/2014)... have decreased by 45% on average over a 35 ... a study on the impact of humans on declining ... benefits invertebrates such as insects, spiders, crustaceans, slugs and ... pest control for crops, decomposition for nutrient cycling, water ... Science and led by UCL, Stanford and ...
Breaking Biology News(10 mins):Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 4NYSCF scientists 1 step closer to cell therapy for multiple sclerosis patients 2Invertebrate numbers nearly halve as human population doubles 2Invertebrate numbers nearly halve as human population doubles 3
... what they want, to paraphrase the Rolling Stones, but sometimes ... that will appear in the May issue of the ... broad sweep of evolutionary changes in life on earth as ... shifts. And yet the amount of variability seen among successive ...
... ,PORTLAND, Ore. April 2, 2010. Countless studies and reports exist ... is the impact on the soil? Should one leave the ... offsite in preparation for replanting the area in the future? ... possible, that the debris remaining on the ground after logging ...
... (ACMGF) has awarded Dr. Marilyn M. Li, of the ... Medicine the 2010-2011 Luminex/ACMGF Award at the ACMG 2010 ... includes a $100,000 grant and is aimed at the ... including the development of research guidelines. "Medical ...
Cached Biology News:Ecologists receive mixed news from fossil record 2Study reveals that logging debris suppresses development of an invasive competitor, Scotch broom 2Dr. Marilyn M. Li, M.D., FACMG, is the 2010 Luminex/ACMGF award recipient 2
Anti-Potassium Channel Kv2.2 Immunogen: Synthetic peptide from rat Kv2.2. Available Date: 38376...
MagSi uniform silica particles coated with a carboxyl group containing polymer, covalently attached to the bead surface....
Antibeta-lactoglobulin monoclonal antibody(CD-2)...
MAb to Vasopressin Preservative: NaN3...
Biology Products: